ARCHIVES

Funding Opportunities

This article is from The Cancer Letter archive.

Vol. 28 No. 37 | October 11, 2002

Download PDF Visit The Full Archive

Related Articles

FDA News: Agency Accepting Nominations For Patient Representatives

May 8, 1998

Gleevec For KIT-positive Tumors Shows 92 Percent Overall Survival

July 29, 2011

EORTC Places Same Number on Phase 2-3 Trials As In U.S.

December 12, 1986

NCI Programs; Pediatric Brain Tumor Consortium Approved In Concepts By BSA; Concepts For Resource Of Arrayed BAC Clones, Support For Radiation Therapy Trials, OH’d

November 23, 1997

Professional Societes; ASCO’s Strength Is In Its Diversify, Lichtor Says

May 21, 1999

FDA Approves Avastin For Recurrent NSCLC

October 27, 2006